An analysis of the CCC19 registry has demonstrated a significant link between receipt of anticancer therapies within 3 months of a COVID-19 diagnosis and an elevated risk for venous thromboembolism

People with cancer who have received COVID-19 vaccination are significantly less likely to experience persistent symptoms after recovery than unvaccinated individuals, irrespective of viral strain, suggest OnCovid data.

A Canadian population-based study has confirmed that people with cancer have an increased risk of breakthrough COVID-19 infection after vaccination, while UK research points to the feasibility of SARS-CoV-2 antibody testing to identify those with the lowest level of vaccine-derived protection.

People with cancer receiving immunotherapy or other anticancer treatments are at increased risk for adverse COVID-19 outcomes if they are also receiving immunosuppressive therapy, suggests a registry-based cohort study.

The frequency of serious adverse event reporting in oncology clinical trials decreased significantly during the COVID-19 pandemic, report US researchers.

A systematic review and meta-analysis has identified global decreases in breast, cervical, and colorectal cancer screening during the early phase of the COVID-19 pandemic.

Among patients with thoracic cancer, the risk for all-cause mortality in the 30 days following COVID-19 infection is highest among those with a poor ECOG performance status or progressive disease, suggests an analysis of data from the CCC19 registry.

Results of a large systematic review and meta-analysis show that people with cancer have a significantly greater risk for death from SARS-CoV-2 infection than their cancer-free peers, particularly if they have lung or hematologic cancer.

A geriatric risk index based on readily available clinical factors can identify older adults with cancer who are most at risk for severe COVID-19, researchers report in The Lancet Healthy Longevity .

Individuals with breast cancer may have a greater risk for acquiring SARS-CoV-2 infection than those with other cancer types, suggests Italian research.

Chris Labaki takes us through his study evaluating temporal changes in the screening, diagnosis, and surgical treatment of genitourinary malignancies during the first year of the COVID-19 pandemic.

TERAVOLT registry investigators have identified seven major risk factors for COVID-19 mortality in patients with thoracic malignancy, with poor ECOG performance status the strongest prognostic marker.

An analysis of the phase 3 PALLAS trial has shown no significant increase in SARS-CoV-2 test positivity and symptomatic infection with the adjuvant use of the CDK4/6 inhibitor palbociclib alongside endocrine therapy in patients with early breast cancer.

Research from three countries adds support for the use of a booster dose of vaccines against SARS-CoV-2 in people with cancer, especially those undergoing active anticancer treatment.

Mortality rates have fallen with time among people with cancer and SARS-CoV-2 infection, show data from the European OnCovid registry.

People with cancer remain susceptible to severe outcomes after developing breakthrough SARS-CoV-2 infection despite being fully vaccinated, research suggests.

People with cancer could benefit from a booster dose of the Pfizer–BioNTech SARS-CoV-2 vaccine, suggest data from Israel.

People with COVID-19 who have recently undergone cancer treatment have a significantly higher risk for death, intensive care unit admission, and hospitalization than those without cancer, suggest data from a large US study.

Around one in seven people with cancer and COVID-19 report persistent symptomatic sequelae of the infection after recovery, suggest data from the OnCovid study.

A prospective cohort study suggests that patients with cancer on active treatment have a higher risk for poor seroconversion after two doses of the Pfizer–BioNTech COVID-19 vaccine than those undergoing active surveillance.